Cipla to Market and Distribute Eli Lilly's Insulin Glargine in India

Cipla Ltd. has announced its partnership with, Eli Lilly and Company (India) Pvt. Ltd., a 100% subsidiary of Eli Lilly and Company, a global multi national, for the marketing and distribution of Lilly’s Basaglar (insulin glargine injection) in India. Under this agreement, Lilly’s Basaglar that is manufactured by Lilly will be marketed and distributed in India by Cipla.

According to Mr. Umang Vohra, Managing Director & Global CEO, Cipla Ltd., diabetes continues to be a focus area for Cipla. “With the launch of strong brand like Basaglar, Cipla will be at the forefront of providing a holistic diabetes care with the most comprehensive portfolio across orals and injectables. Cipla’s focus continues to revolve around care continuum approach for the patients it serves and create greater access to high quality treatment and medication.”

According to Mr. Luca Visini, Managing Director, Lilly India “this strategic partnership leverages Lilly’s commitment to bring innovation to people suffering from diabetes in India and Cipla’s strong on-ground footprint across the country.”

“While insulin has been a mainstay of diabetes treatment for many years, when it comes to initiating basal insulin therapy, people with diabetes still face several emotional and practical challenges. We believe that the launch of Basaglar, with its support for healthcare professionals and patients, is an important milestone in our journey to contribute to better diabetes care in India through our portfolio of innovative therapies and solutions,” he added.Cipla expects to start commercialising Basaglar in India by end of 2018.